Sarepta Therapeutics (SRPT) Cash from Financing Activities (2010 - 2026)

Sarepta Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $241000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 98.07% year-over-year to $241000.0; the TTM figure through Mar 2026 stood at -$180.6 million (down 256.83% YoY), while the FY2025 annual figure was -$168.3 million, down 234.88% from the prior year.
• Cash from Financing Activities was $241000.0 for Q1 2026 at Sarepta Therapeutics, up from -$39.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $216.4 million in Q3 2022 to a low of -$117.8 million in Q3 2025.
• Historically, Cash from Financing Activities has averaged $18.5 million across 5 years, with a median of $10.7 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities jumped 3567.05% in 2022, then plunged 956.22% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $10.7 million in 2022, then plunged by 81.92% to $1.9 million in 2023, then soared by 2421.41% to $49.0 million in 2024, then tumbled by 180.03% to -$39.2 million in 2025, then soared by 100.61% to $241000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $241000.0 (Q1 2026), -$39.2 million (Q4 2025), and -$117.8 million (Q3 2025), per Business Quant data.